[go: up one dir, main page]

ES2126094T3 - Tratamiento de la enfermedad inflamatoria de los intestinos con inhibidores del interferon-gamma. - Google Patents

Tratamiento de la enfermedad inflamatoria de los intestinos con inhibidores del interferon-gamma.

Info

Publication number
ES2126094T3
ES2126094T3 ES94905355T ES94905355T ES2126094T3 ES 2126094 T3 ES2126094 T3 ES 2126094T3 ES 94905355 T ES94905355 T ES 94905355T ES 94905355 T ES94905355 T ES 94905355T ES 2126094 T3 ES2126094 T3 ES 2126094T3
Authority
ES
Spain
Prior art keywords
interferon
treatment
intestines
inflammatory disease
gamma inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94905355T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Rebecca H R Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2126094T3 publication Critical patent/ES2126094T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A UN METODO PARA LA PREVENCION O TRATAMIENTO DE ENFERMEDADES INTESTINALES INFLAMATORIAS MEDIANTE LA ADMINISTRACION DE UN INHIBIDOR DE INTERFERONES-{GA}. LA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS Y A MOLECULAS BIESPECIFICAS UTILES EN TAL METODO.
ES94905355T 1992-12-29 1993-12-09 Tratamiento de la enfermedad inflamatoria de los intestinos con inhibidores del interferon-gamma. Expired - Lifetime ES2126094T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99783592A 1992-12-29 1992-12-29

Publications (1)

Publication Number Publication Date
ES2126094T3 true ES2126094T3 (es) 1999-03-16

Family

ID=25544454

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94905355T Expired - Lifetime ES2126094T3 (es) 1992-12-29 1993-12-09 Tratamiento de la enfermedad inflamatoria de los intestinos con inhibidores del interferon-gamma.

Country Status (12)

Country Link
US (5) US6558661B1 (es)
EP (1) EP0695189B1 (es)
JP (1) JP3887011B2 (es)
AT (1) ATE173630T1 (es)
AU (1) AU678429B2 (es)
CA (1) CA2148907C (es)
DE (1) DE69322289T2 (es)
DK (1) DK0695189T3 (es)
ES (1) ES2126094T3 (es)
IL (2) IL108007A (es)
WO (1) WO1994014467A1 (es)
ZA (1) ZA939577B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US6558661B1 (en) * 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors
US20020025316A1 (en) 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
AU2452797A (en) * 1996-04-10 1997-10-29 Board Of Trustees Of The University Of Illinois, The Interferon-gamma anti-inflammatory methods, compounds, and pharmaceutical compositions
ES2251248T3 (es) 1998-12-09 2006-04-16 Protein Design Labs, Inc. Uso de anticuerpos contra il-12 para tratar la psoriasis.
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US6348316B1 (en) 2000-04-12 2002-02-19 Cedars-Sinai Medical Center Genetic testing for determining the risk of pouchitis development
GB0009503D0 (en) * 2000-04-17 2000-06-07 Univ Liverpool Screening method for compounds
CA2407426A1 (en) 2000-04-28 2001-11-08 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
EP1485476A2 (en) * 2002-03-12 2004-12-15 Novo Nordisk A/S Dimeric tf antagonist
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス， インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
AU2003231802A1 (en) * 2002-05-17 2003-12-02 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2004004636A2 (en) * 2002-07-03 2004-01-15 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
US20060104946A1 (en) * 2002-08-23 2006-05-18 Zymogenetics, Inc. Method for treating inflammatory bowel disease
AU2003285874A1 (en) * 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
NZ537089A (en) * 2003-02-24 2007-07-27 Morinaga Milk Industry Co Ltd Interleukin 6 production inhibitor
ATE407698T1 (de) 2003-04-23 2008-09-15 Medarex Inc Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
GB0323793D0 (en) * 2003-10-10 2003-11-12 Imp College Innovations Ltd Methods
ATE383367T1 (de) * 2003-11-19 2008-01-15 Glycomimetics Inc Spezifischer antagonist sowohl für e- als auch p- selektine
WO2005054264A2 (en) * 2003-11-19 2005-06-16 Glycomimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
US20050260155A1 (en) * 2004-05-18 2005-11-24 Gopala Kovvali Compositions and methods for treatment of ulcerative colitis
PT1781705E (pt) 2004-06-21 2014-12-23 Medarex Llc Anticorpos contra recetor i do interferão alfa e as suas utilizações
US20060040258A1 (en) * 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
ES2381203T3 (es) * 2005-01-27 2012-05-24 Novimmune Sa Anticuerpos anti-interferón gamma humanos y métodos de uso de los mismos
US20060205090A1 (en) * 2005-03-14 2006-09-14 Newton Michael W Water-soluble conjugates for electrochemical detection
US20090036386A1 (en) * 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
ATE528311T1 (de) * 2005-08-09 2011-10-15 Glycomimetics Inc Glycomimetische inhibitoren des pa-il-lectins, pa-iil-lectins oder beider lectine aus pseudomonas
EP1934236B1 (en) * 2005-09-02 2012-11-21 GlycoMimetics, Inc. Heterobifunctional pan-selectin inhibitors
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
WO2008060378A2 (en) 2006-10-12 2008-05-22 Glycomimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
JP5511390B2 (ja) * 2007-02-09 2014-06-04 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの置換体を有する糖模倣体の使用方法
US8039442B2 (en) * 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8895510B2 (en) * 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
CN102088983B (zh) * 2008-06-13 2013-01-30 糖模拟物有限公司 利用选择的糖模拟化合物的血液癌症的治疗
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
EA201170028A1 (ru) * 2008-07-02 2011-12-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US8410066B2 (en) 2009-05-01 2013-04-02 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
AU2012340624B2 (en) 2011-11-23 2017-08-24 Amgen Inc. Methods of treatment using an antibody against interferon gamma
HUE036253T2 (hu) 2011-12-22 2018-06-28 Glycomimetics Inc E-szelektin antagonista vegyületek
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
DK2928476T3 (en) 2012-12-07 2018-05-22 Glycomimetics Inc RELATIONSHIPS, COMPOSITIONS AND METHODS OF USING E-SELECTIN ANTAGONISTS FOR MOBILIZATION OF HEMATOPOIETIC CELLS
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
US10519181B2 (en) 2014-12-03 2019-12-31 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
US20180051078A1 (en) * 2015-03-16 2018-02-22 Cedars-Sinai Medical Center Methods of treating inflammatory bowel disease with ifn-gamma therapy
BR112017023867A2 (pt) 2015-05-07 2018-07-24 Novimmune Sa métodos e composições para diagnóstico e tratamento de distúrbios em pacientes com níveis elevados de cxcl9 e outros biomarcadores
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
EP3405473A1 (en) 2016-01-22 2018-11-28 GlycoMimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
US10266745B2 (en) * 2017-02-03 2019-04-23 Saudi Arabian Oil Company Anti-bit balling drilling fluids, and methods of making and use thereof
WO2018169853A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
JP7275131B2 (ja) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
WO2019133878A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
CN111867601A (zh) 2018-03-05 2020-10-30 糖模拟物有限公司 用于治疗急性髓系白血病及相关病症的方法
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
GB8519848D0 (en) 1985-08-07 1985-09-11 Schweiz Rotes Kreuz Treatment of chronic inflammatory disease
IL78444A (en) 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
IL88378A (en) 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0393502T3 (da) * 1989-04-19 1996-03-04 Hoffmann La Roche Opløselige interferon-gamma-receptorer og fremgangsmåder til fremstilling heraf
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL91562A0 (en) 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
EP0528847B1 (en) 1990-04-24 1994-09-28 Schering Corporation Soluble, truncated gamma-interferon receptors
EP0550650B1 (en) 1990-09-27 1995-12-27 Schering Corporation Antagonists of human gamma interferon
US6558661B1 (en) * 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors
CA2114168A1 (en) 1993-03-05 1994-09-06 Zlatko Dembic Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides
JPH0746628A (ja) * 1993-06-29 1995-02-14 Toshiba Corp 画像信号符号化装置及び画像信号復号化装置
CA2352572C (en) * 1998-12-01 2010-04-20 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
AU2003231802A1 (en) 2002-05-17 2003-12-02 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
US20050019323A1 (en) * 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Also Published As

Publication number Publication date
IL124478A0 (en) 1998-12-06
IL108007A0 (en) 1994-04-12
US20030012787A1 (en) 2003-01-16
DE69322289T2 (de) 1999-05-20
AU5898894A (en) 1994-07-19
ZA939577B (en) 1995-06-21
US20070020268A1 (en) 2007-01-25
US20070104712A1 (en) 2007-05-10
DE69322289D1 (de) 1999-01-07
WO1994014467A1 (en) 1994-07-07
JP3887011B2 (ja) 2007-02-28
CA2148907C (en) 2008-07-08
EP0695189A1 (en) 1996-02-07
EP0695189B1 (en) 1998-11-25
ATE173630T1 (de) 1998-12-15
JPH08504817A (ja) 1996-05-28
DK0695189T3 (da) 1999-08-09
US6558661B1 (en) 2003-05-06
CA2148907A1 (en) 1994-07-07
IL108007A (en) 2005-08-31
US7449176B2 (en) 2008-11-11
US20030012790A1 (en) 2003-01-16
AU678429B2 (en) 1997-05-29
US7300656B2 (en) 2007-11-27

Similar Documents

Publication Publication Date Title
ES2126094T3 (es) Tratamiento de la enfermedad inflamatoria de los intestinos con inhibidores del interferon-gamma.
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
PT705100E (pt) Guanidinas substituidas terapeuticas
ES2196190T3 (es) Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.
LV12209A (lv) Ar fenilgrupu aizvietoti heterocikli ka ciklooksigenazes-2 inhibitori
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
DE69528528D1 (de) Thrombin-inhibitoren
DE69620161D1 (de) Thrombininhibitoren
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
EA199900837A1 (ru) Способ применения ингибиторов циклооксигеназы-2 для предупреждения сердечно-сосудистых расстройств
ES2166823T3 (es) Nuevos derivados pirrolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DK0603301T3 (da) Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist
DE69413789D1 (de) 2-amino-4-phenyl-4-oxo-buttersäure-derivate mit kynureninase und/oder kynurenin-3-hydroxylase inhibierender wirkung
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
ITRM920222A0 (it) Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
ES2091031T3 (es) Uso de acido hialuronico para prevenir la reestenosis arterial.
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
ES2054790T3 (es) Compuestos que tienen actividad cardiovascular.
ATE218877T1 (de) Bowman-birk-inhibitorzusammensetzungen zur behandlung von entzündungskrankheiten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 695189

Country of ref document: ES